Human epidermal growth factor receptor 2 (HER2/neu) supraexpression in the mammary tumors

Romanian Journal of Morphology and Embryology

Volumn 52, Issue 3 SUPPL., 2012, Pages 1101-1105

  Moise, M ^a   Motoc, A ^a   Rǎducan, Andreea ^a   Raducan S ^a   Niculescu, V ^a   Niculescu, M ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

HER2 neu supraexpression; Immunohistochemistry; Mammary tumors

Indexed keywords

EID: 84865778620     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Schroeder W, Biesterfeld S, Zillessen S, Rath W, Epidermal growth factor receptor - immunohistochemical detection and clinical significance for treatment of primary breast cancer, Anticancer Res, 1997, 17(4A):2799-2802.
2. Graus-Porta D, Beerli RR, Daly JM, Hynes NE, ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling, EMBO J, 1997, 16(7):1647-1655.
3. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA, erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells, Science, 1987, 237(4811):178-183.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 1987, 235(4785):177-182.
5. Hayes DF, Thor AD, c-erbB-2 in breast cancer: development of a clinically useful marker, Semin Oncol, 2002, 29(3):231-245.
6. Thor AD, Liu S, Edgerton S, Moore D 2nd, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP, Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer, J Clin Oncol, 2000, 18(18):3230-3239.
7. Ross JS, Fletcher JA, The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy, Stem Cells, 1998, 16(6):413-428.
8. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN, Targeted therapy in breast cancer: the HER-2/neu gene and protein, Mol Cell Proteomics, 2004, 3(4):379-398.
9. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L et al., HER-2/neu node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma, J Clin Oncol, 1992, 10(4):599-605.
10. Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, Ciatto S, Prognostic significance of c-erbB-2 expression in node negative breast cancer, Br J Cancer, 1993, 67(3):625-629.
11. Stark A, Hulka BS, Joens S, Novotny D, Thor AD, Wold LE, Schell MJ, Melton LJ 3rd, Liu ET, Conway K, HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer, J Clin Oncol, 2000, 18(2):267-274.
12. De Placido S, De Laurentiis M, Carlomagno C, Gallo C, Perrone F, Pepe S, Ruggiero A, Marinelli A, Pagliarulo C, Panico L, Pettinato G, Petrella G, Bianco AR, Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer, Clin Cancer Res, 2003, 9(3):1039-1046.
13. Cooke T, Reeves J, Lanigan A, Stanton P, HER2 as a prognostic and predictive marker for breast cancer, Ann Oncol, 2001, 12(Suppl 1):S23-S28.
14. Cooke T, Reeves J, Lanigan A, Stanton P, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group, Lancet, 1992, 339(8785):71-85.
15. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J Natl Cancer Inst, 1998, 90(18):1371-1388.
16. Moreno A, Lloveras B, Figueras A, Escobedo A, Ramon JM, Sierra A, Fabra A, Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers, Mod Pathol, 1997, 10(11):1088-1092.
17. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L, Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens, J Clin Oncol, 2002, 20(14):3095-3105.
18. Baker JA, Rosen EL, Lo JY, Gimenez EI, Walsh R, Soo MS, Computer-aided detection (CAD) in screening mammography: sensitivity of commercial CAD systems for detecting architectural distortion, AJR Am J Roentgenol, 2003, 181(4):1083-1088.